Intra-cellular therapies reports second quarter 2024 financial results, provides corporate update and raises 2024 caplyta sales guidance

Caplyta q2 2024 net product sales were $161.3 million, compared to $110.1 million for the same period in 2023, representing a 46% increase

ITCI Ratings Summary

ITCI Quant Ranking